Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.
复制标题
DOI：
10.3389/fimmu.2020.585385
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Scheinberg DA
中科院分区：
文献类型：
--
作者：
Jones HF;Molvi Z;Klatt MG;Dao T;Scheinberg DA
在过去的三十年里，使用与细胞内肿瘤相关或肿瘤特异性抗原反应的T细胞一直是癌症免疫治疗的一种有前途的策略，但该方法受到对T细胞受体（TCR）复杂功能和特异性的有限理解的限制。基于TCR和T细胞的新方法正在开发中，包括具有增强的TCR亲和力的工程化过继T细胞、TCR模拟抗体和T细胞重定向双特异性试剂。这些新的治疗方式是令人兴奋的机会，通过这些机会，TCR识别可以进一步用于治疗益处。在这篇综述中，我们总结了基于TCR的治疗策略的发展，并重点关注这些强大的治疗方式的疗效和效力与特异性之间的平衡，以及可能的毒性。
The use of T cells reactive with intracellular tumor-associated or tumor-specific antigens has been a promising strategy for cancer immunotherapies in the past three decades, but the approach has been constrained by a limited understanding of the T cell receptor’s (TCR) complex functions and specificities. Newer TCR and T cell-based approaches are in development, including engineered adoptive T cells with enhanced TCR affinities, TCR mimic antibodies, and T cell-redirecting bispecific agents. These new therapeutic modalities are exciting opportunities by which TCR recognition can be further exploited for therapeutic benefit. In this review we summarize the development of TCR-based therapeutic strategies and focus on balancing efficacy and potency versus specificity, and hence, possible toxicity, of these powerful therapeutic modalities.